CHRS - CONSENSUS CO - Coherus Biosciences

Coherus Biosciences (CHRS) management is currently aggressively reducing debt by divesting non-core assets, while the market assesses the potential for a return to profitability and the launch of Loqtorzi. This price chart reflects the market reaction to the company's strategy, which generates revenue from biosimilars and unique oncology drugs with premium pricing. Business resilience relies on patent protection and hospital sales, and the current figure is 7.72.

The strategy of Coherus Biosciences (CHRS) to fund oncology innovations using biosimilar revenues directly impacts the current consensus target price. This indicator represents a weighted average of expert expectations, reflecting the business's fundamental value through the lens of future cash flows, which allows investors to assess the company's market potential relative to its current capitalization.